Success Metrics

Clinical Success Rate
93.3%

Based on 14 completed trials

Completion Rate
93%(14/15)
Active Trials
0(0%)
Results Posted
21%(3 trials)
Terminated
1(7%)

Phase Distribution

Ph phase_1
13
87%
Ph phase_2
2
13%

Phase Distribution

13

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
13(86.7%)
Phase 2Efficacy & side effects
2(13.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

93.3%

14 of 15 finished

Non-Completion Rate

6.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Completed(14)
Terminated(1)

Detailed Status

Completed14
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
93.3%
Most Advanced
Phase 2

Trials by Phase

Phase 113 (86.7%)
Phase 22 (13.3%)

Trials by Status

completed1493%
terminated17%

Recent Activity

0 active trials
Showing 5 of 15
completedphase_1

A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

NCT04095221
completedphase_1

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

NCT04023669
completedphase_1

Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

NCT02808650
completedphase_1

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT02649764
completedphase_2

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

NCT03414047
View all 15 trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT04095221Phase 1

A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma

Completed
NCT04023669Phase 1

Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors

Completed
NCT02808650Phase 1

Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Completed
NCT02649764Phase 1

Prexasertib (LY2606368), Cytarabine, and Fludarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Completed
NCT03414047Phase 2

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

Completed
NCT03057145Phase 1

Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

Completed
NCT03495323Phase 1

A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

Completed
NCT02124148Phase 1

A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer

Completed
NCT02735980Phase 2

A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer

Completed
NCT02778126Phase 1

A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer

Completed
NCT03735446Phase 1

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

Terminated
NCT02555644Phase 1

A Study of Prexasertib (LY2606368) With Chemotherapy and Radiation in Participants With Head and Neck Cancer

Completed
NCT02860780Phase 1

A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer

Completed
NCT02514603Phase 1

A Study of Prexasertib (LY2606368) in Japanese Participants With Advanced Cancers

Completed
NCT01115790Phase 1

A Phase 1 Study in Participants With Advanced Cancer

Completed

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15